Exploring the Role of Antibiotics in Hospice Care.

J Frailty Aging

Gabriele Ghidini, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy,

Published: November 2024

Background: The decision regarding the use of antibiotics in hospice care, whether to initiate, defer, or discontinue therapy, presents challenges. This study aims to explore the characteristics of terminally ill patients associated with antimicrobial use in hospice.

Methods: Data are from a registry study enrolling patients admitted to hospice after discharge from a hospital. Three-hundred-sixty-six persons aged 18 and older were considered for the present analysis. Collected data encompassed demographic information, medical history, and outcomes assessed through a comprehensive geriatric assessment.

Results: Among the patients admitted to the hospice, 242 individuals did not receive antibiotics (Group A), and 91 (24.6%) were already undergoing antibiotic therapy at admission. Of these, 59 (65.6%) patients (Group B) continued the treatment, while 32 (35.6%; Group C) discontinued it. Additionally, 33 patients (Group D) initiated an antibiotic treatment during their hospice stay. Patients undergoing antibiotic therapy (Group D) presented higher residual functions than the other groups, especially compared to Group C (p<0.001). The four groups also differed in mortality risk. In particular, Cox proportional hazard models indicated that Group D presented a lower risk of death than Group A, even after adjustment for age, sex, estimated poor prognosis and two different performance status (PS ECOG, Karnofsky PS).

Conclusion: A relatively high number of persons admitted to the hospice receive antibiotic therapy without apparent benefit. The decision to prescribe antibiotics in hospice care appears to be based on the patient's functional performance and estimated prognosis.

Download full-text PDF

Source
http://dx.doi.org/10.14283/jfa.2024.74DOI Listing

Publication Analysis

Top Keywords

antibiotics hospice
8
hospice care
8
patients admitted
8
admitted hospice
8
undergoing antibiotic
8
antibiotic therapy
8
patients group
8
patients
6
group
6
hospice
5

Similar Publications

Antimicrobial susceptibility and epidemiological types of Legionella pneumophila human isolates from Italy (1987-2020).

J Glob Antimicrob Resist

January 2025

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy; ESCMID Study Group for Legionella Infections (ESGLI), Basel, Switzerland. Electronic address:

Background: Although antimicrobial resistance has not yet emerged as an overarching problem for Legionella pneumophila (Lp) infection, the description of clinical and environmental strains resistant to fluoroquinolones and macrolides is a cause of concern. This study aimed to investigate the antimicrobial susceptibility of Lp human isolates in Italy.

Methods: A total of 204 Lp clinical isolates were tested for sensitivity to nine antibiotics using the broth microdilution assay (BMD).

View Article and Find Full Text PDF

Real-time monitoring by interferometric light microscopy of phage suspensions for personalised phage therapy.

Sci Rep

December 2024

Pharmacy Department, Hospices Civils de Lyon, Hôpital E. Herriot, Plateforme FRIPHARM, 69437, Lyon, France.

Phage therapy uses viruses (phages) against antibiotic resistance. Tailoring treatments to specific patient strains requires stocks of various highly concentrated purified phages. It, therefore, faces challenges: titration duration and specificity to a phage/bacteria couple; purification affecting stability; and highly concentrated suspensions tending to aggregate.

View Article and Find Full Text PDF

Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial.

EBioMedicine

January 2025

Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Section for Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway. Electronic address:

Background: The Bari-SolidAct randomized controlled trial compared baricitinib with placebo in patients with severe COVID-19. A post hoc analysis revealed a higher incidence of serious adverse events (SAEs) among SARS-CoV-2-vaccinated participants who had received baricitinib. This sub-study aimed to investigate whether vaccination influences the safety profile of baricitinib in patients with severe COVID-19.

View Article and Find Full Text PDF

Fumagillin Shortage: How to Treat Microsporidiosis in Solid Organ Transplant Recipients in 2024?

Transpl Int

December 2024

Service de Parasitologie-Mycologie, 3IHP, Inserm U1071, M2iSH, USC-INRAE 1382, Université Clermont Auvergne, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Unlabelled: Intestinal microsporidiosis caused by is an opportunistic infection that especially affects solid organ transplant (SOT) recipients. Management revolves around tapering the immunosuppressive regimen and/or using a specific anti-microsporidia treatment, but only fumagillin has demonstrated efficacy for treatment of this infection. Since fumagillin has been commercially discontinued, nitazoxanide is increasingly being used in this indication.

View Article and Find Full Text PDF

This case report presents a 77-year-old female with dementia and hypertension who experienced reduced consciousness during hydrotherapy. She was found to have hypotension, a low Glasgow Coma Scale score, and right thigh pain. Blood work showed acute kidney injury and elevated inflammatory markers, while imaging revealed surgical emphysema in the right thigh and pelvis without trauma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!